GLSI Greenwich LifeSciences Inc.: רווח למניה ב-12 החודשים האחרונים

Greenwich LifeSciences Inc. (GLSI) - לוגו תאגידי

Geopolitical conflicts and sanctions are restricting access to global patient cohorts, hindering the drug development efforts of Greenwich LifeSciences (GLSI). The share price retrospective with the -11.50 metric demonstrates the impact of final-stage drug testing, toward which all of the company's capital is directed. Business protection is ensured by strict FDA oversight and exclusive vaccine patents, which create insurmountable barriers to entry for new market players.

רווח נקי למניה (EPS TTM) Greenwich LifeSciences, Inc (GLSI): לתקופה 11.02.2024 - 17.11.2026

Greenwich LifeSciences Inc - פילוחים אנליטיים ומדדי מפתח (GLSI)

- ציטוטים נוכחיים ותחזית שווי ממוצעת:
ניתוח ראשוני של החברה:Greenwich LifeSciences, Inc. GLSI
דוגמת מוצר של Greenwich LifeSciences, Inc

Year-over-year (YoY) EPS growth (TTM) measures the rate of change in net income per share, comparing the current trailing twelve months to the previous period to identify actual capital efficiency. Investors utilize this metric to strip away GAAP paper adjustments from actual cash flow. The YoY EPS dynamics over the last 12 months help assess whether the reputation of Greenwich LifeSciences (GLSI) in the fight against breast cancer is backed by real financial growth. This protects capital from asset overvaluation based solely on patient hopes.